Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind study of teplizumab versus placebo in recently diagnosed stage 3 type 1 diabetes
CTR20253851Phase 3Active
- Sponsor
- Sanofi
- Start
- Dec 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of teplizumab in diabetes mellitus type 1 (T1D), sponsored by Sanofi. Started Dec 2025; status: active.
02
Drugs
teplizumab
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on CTR20253851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253851.